ClinicalTrials.gg
RecruitingNCT05791786AFEUpdated May 8, 2026

The Establishment of a Registry and a Biorepository of Patients With Suspected Amniotic Fluid Embolism (AFE)

An observational study in Amniotic Fluid Embolism, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by The University of Texas Health Science Center, Houston · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Sex
All
01

Study summary

To establish a clinical registry of suspected cases of AFE. The existing registry will be migrated to a new platform,

Read the detailed description

The registry and the biorepository have prospective and retrospective components.

The prospective component of the registry and the biorepository focuses on the collection of demographic, clinical, and biological material of patients prospectively identified as having the AFE syndrome, including the collection of future samples from survivors and related individuals. Typically, healthcare providers, family members of an affected patient, or patients themselves contact the AFE Foundation. The AFE Foundation provides information about the natural history of the syndrome and its outcomes and invites patients to participate in the registry and biorepository. The AFE Foundation obtains informed consent from patients or next of kin for enrollment in this observational study. There is no randomization or placebo group for this registry as it is exclusively an observational study. If maternal specimens are available pre- and post-event during the hospital admission for delivery, these samples will also be collected from each patient. The only group assignment will be the subjects with a diagnosis of AFE and the subjects' family members including the partner(s) and child (children).

The retrospective component of the registry consists of obtaining clinical information and biological material from patients who have been previously affected by the AFE syndrome. This objective includes obtaining medical records, patient-provided information, pathology reports, autopsy reports, and tissue blocks. Biological samples can also be obtained from survivors and relatives to determine whether there are biomarkers in previously affected patients or whether biomarkers can be elicited from the stimulation of peripheral blood cells. In addition to collecting data and specimens from the patients that are consented and enrolled through the registry, a query of all maternal deaths within 24 hours of birth between 1/2012 to 1/2023 will be performed at the Hermann Hospital system to identify if any of these deaths occurred secondary to AFE. The investigators intend to perform a detailed chart review and collect otherwise discarded tissue if available from the respective hospital to perform special immunohistochemistry staining among women who underwent autopsy.

02

Conditions studied

  • Amniotic Fluid Embolism
03

In context

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.

Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant and postpartum women, survivors, offspring, and relatives of patients with suspected AFE through enrollment or chart review.

Eligibility criteria

Inclusion Criteria for participants of the AFE registry and biorepository include affected individuals diagnosed with AFE (see below).

  • All subjects or their next of kin must be able to provide a signed and dated form.
  • In the case of lethal AFE, the surviving family member or next of kin must be able to provide a signed and dated informed consent form with an accompanying death certificate and proof of legal kinship.
  • Participants are expected to be willing to permit collection of data about their affected pregnancy, previous and future pregnancies, and their current and future health conditions.
  • Providing biological samples is not required for enrollment.
  • Any maternal death in the Hermann Hospital System suspected of having an AFE within 24 hours of childbirth between 1/2012 and 1/2023 will also be included for data analysis and biospecimen studies
  • Medical records will be abstracted into a comprehensive case report form and then reviewed by a team of three experts with consensus to determine case classification of three categories, according to criteria previously reported and based on data generated from the previously existing registry:

    (1) Classic AFE is defined by the following indicators:

  • Acute hypotension or cardiac arrest,
  • Acute hypoxia, defined as dyspnea, cyanosis, or respiratory arrest,
  • Coagulopathy, defined as laboratory evidence of intravascular consumption or fibrinolysis or severe clinical hemorrhage in the absence of other explanations,
  • Onset of the above during labor, cesarean section, or dilation and evacuation or within 30 minutes post-partum, and
  • Absence of any other significant confounding condition or potential explanation for the signs and symptoms observed.

    (2) Not AFE:

  • Anything that clinically appears to be a likely result of another pathophysiology, e.g., delayed treatment of postpartum hemorrhage from uterine atony.

    (3) Atypical AFE:

  • Subjective determination by the chart reviewer that lies between "classic" and "not," e.g., the patient presents some of the registry criteria and no other explanation.

    (4) Indeterminate: There is not sufficient information to classify in 1-3 above.

The classification of AFE is for research purposes only.

Exclusion Criteria:

  • The inability of an individual to provide a signed and dated informed consent form or those who do not wish to participate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
2 Weeks
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • AFE

    participants of the AFE registry and biorepository include affected individuals diagnosed with AFE All subjects or their next of kin must be able to provide a signed and dated informed consent form. In the case of lethal AFE, the surviving family member or next of kin must be able to provide a signed and dated informed consent form with an accompanying death certificate and proof of legal kinship

    Other: Patient

Interventions

  • OtherPatient

    affected individuals diagnosed with AFE

06

What researchers measure

Primary outcomes

  1. To establish a clinical registry of suspected cases of AFE

    The existing registry will be migrated to a new platform, thus to enhance and strengthen the content and the quality of the data obtained.

    Time frame: 1 year

  2. The existing registry will be migrated to a new platform, thus to enhance and strengthen the content and the quality of the data obtained.

    biological materials would be sought from mothers, their children, and other related individuals

    Time frame: 2 weeks

  3. To obtain clinical data and biological specimens from individuals previously enrolled in the registry

    This objective includes the review of autopsy material and pathology reports, as well as the collection of biological material of survivors and members of the family, to determine whether there is a susceptibility to the AFE syndrome

    Time frame: 3 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Oct 2031, 110 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2023
First posted
Mar 30, 2023
StartActual
Jul 5, 2022
Primary completionEst.
Oct 1, 2031
CompletionEst.
Dec 31, 2031
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05791786
Collaborators
Amniotic Fluid Embolism (AFE) Foundation
Responsible party
Irene Stafford (Associate Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Mar 30, 2023
Start date
Jul 5, 2022
Primary completion
Oct 1, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
May 8, 2026

Study contacts

Miranda Klassen
Contact
miranda@afesupport.org
760-444-5505
Irene Stafford, MD
Contact
irene.stafford@uth.tmc.edu
713-500-6412
Irene Stafford, MD
principal investigator · UT Health Science Center Health Science Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion